<div id="readability-page-1"><p>Dyne Therapeutics (NASDAQ:DYN - Get Free Report) issued its earnings results on Monday. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.01, RTT News reports. During the same period in the prior year, the business earned ($1.05) EPS.</p><div><p><span></span><span>Get <strong>Dyne Therapeutics</strong> alerts:</span></p></div><h2>Dyne Therapeutics Stock Performance</h2><p>Dyne Therapeutics stock traded up $0.61 during trading hours on Monday, hitting $18.22. 336,444 shares of the stock traded hands, compared to its average volume of 2,062,577. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25. The firm's 50 day moving average price is $18.05 and its 200-day moving average price is $18.59. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -5.15 and a beta of 1.08. Dyne Therapeutics has a 1 year low of $8.06 and a 1 year high of $25.00. </p><h2>Analyst Ratings Changes</h2><p>DYN has been the subject of a number of research analyst reports. Chardan Capital  reaffirmed a &#34;buy&#34; rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Wall Street Zen lowered Dyne Therapeutics from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research report on Saturday, May 2nd. HC Wainwright decreased their target price on Dyne Therapeutics from $60.00 to $50.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, March 3rd. Morgan Stanley decreased their target price on Dyne Therapeutics from $50.00 to $47.00 and set an &#34;overweight&#34; rating for the company in a research report on Monday, March 2nd. Finally, JPMorgan Chase &amp; Co. decreased their target price on Dyne Therapeutics from $17.00 to $16.00 and set a &#34;neutral&#34; rating for the company in a research report on Tuesday, January 20th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued  a Buy rating, two have issued  a Hold rating and one  has issued  a Sell rating to the company's stock. According to MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $35.14.</p><p><b>Get Our Latest Stock Analysis on Dyne Therapeutics</b></p><h2>Insiders Place Their Bets</h2><p>In other Dyne Therapeutics news, Director Jason P. Rhodes sold 83,219 shares of the business's stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total transaction of $1,512,921.42. Following the sale, the director owned 7,962 shares in the company, valued at approximately $144,749.16. The trade was a 91.27% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,552,911 shares of company stock worth $29,694,469. 20.77% of the stock is currently owned by insiders. </p><h2>Institutional Trading of Dyne Therapeutics</h2><p>A number of hedge funds have recently modified their holdings of DYN. T. Rowe Price Investment Management Inc. raised its holdings in  Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the period.  Orbis Allan Gray Ltd acquired a new position in  Dyne Therapeutics in the 4th quarter worth about $93,926,000.  Adage Capital Partners GP L.L.C. acquired a new position in  Dyne Therapeutics in the 2nd quarter worth about $30,378,000.  Marshall Wace LLP raised its holdings in  Dyne Therapeutics by 572.9% in the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company's stock worth $38,119,000 after purchasing an additional 2,565,570 shares during the period.  Finally, Vestal Point Capital LP raised its holdings in  Dyne Therapeutics by 281.4% in the 3rd quarter. Vestal Point Capital LP now owns 2,775,000 shares of the company's stock worth $35,104,000 after purchasing an additional 2,047,500 shares during the period. Hedge funds and other institutional investors own  96.68% of the company's stock. </p><h2>About Dyne Therapeutics</h2> (Get Free Report)<p>Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.  </p><p>Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.</p><h2>Read More</h2><ul><li>Five stocks we like better than Dyne Therapeutics</li><li>AI Dividend Increases: 3 Massive Winners Boosting Payouts</li><li>Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader</li><li>5 Stocks Positioned to Benefit From the AI Inference Boom</li><li>Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFlO"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Dyne Therapeutics Right Now?</h2><p>Before you consider Dyne Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.</p><p>While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

<p>Dyne Therapeutics (NASDAQ:DYN) announced its quarterly earnings, reporting an EPS of ($0.73), surpassing estimates of ($0.74). This is an improvement from the previous year's EPS of ($1.05). The stock rose to $18.22, with a market cap of $3.01 billion. Analysts have mixed ratings, with a consensus rating of "Moderate Buy" and a target price of $35.14. Insiders have sold significant shares recently, and institutional investors hold 96.68% of the stock. Dyne focuses on gene regulation therapies for rare diseases, including Duchenne muscular dystrophy.</p>

Market Beat

Dyne Therapeutics

Ark Genomic Revolution ETF

VG Health

iShares Biotechnology ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Biotech

Morgan Stanley

JPMorgan Chase

T. Rowe Price

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Dyne Therapeutics (NASDAQ:DYN) Announces Earnings Results